血浆代谢组学和脂质组学可按周围神经病变状态区分肥胖个体
这项观察性研究对平均3级肥胖的参与者(伴周围神经病变n=44、不伴n=44,按血糖状态匹配)与瘦型无神经病变对照(n=43)进行血浆全局代谢组学和靶向脂质组学分析。瘦型与肥胖比较中,γ-谷氨酰和支链氨基酸代谢及三酰甘油差异最显著。肥胖个体内按神经病变状态分层,多胺、嘌呤生物合成和苯甲酸代谢存在差异,二酰甘油是区分神经病变状态最显著的脂质子通路。按血糖状态分层不影响按神经病变状态的区分。
要点
- 瘦型与肥胖比较中,γ-谷氨酰和支链氨基酸代谢及三酰甘油差异最显著。
- 肥胖个体内按周围神经病变状态分层,多胺、嘌呤生物合成和苯甲酸代谢存在差异。
- 二酰甘油是区分肥胖个体神经病变状态最显著的脂质子通路,按血糖状态分层不影响区分。
核心结论
- 在平均3级肥胖的样本中,肥胖可能是与糖尿病前期或2型糖尿病强度相当的周围神经病变驱动因素,至少就血浆代谢组学和脂质组学谱而言。
- 代谢和复杂脂质通路可区分伴或不伴周围神经病变的肥胖个体,且不依赖于血糖状态。
研究设计与样本
- 观察性研究,对平均3级肥胖参与者(伴周围神经病变n=44、不伴n=44,按血糖状态匹配)与瘦型无神经病变对照(n=43)进行血浆全局代谢组学和靶向脂质组学分析。
- 数据分析采用Wilcoxon检验、逻辑回归、偏最小二乘判别分析和组套索(group-lasso),并按糖尿病前期和2型糖尿病状态进行亚组分析。
主要发现
- 瘦型与肥胖比较(不论周围神经病变状态)中,代谢组学分析发现γ-谷氨酰和支链氨基酸代谢差异最显著,脂质组学发现三酰甘油差异最显著。
- 肥胖个体内按周围神经病变状态分层,发现多胺、嘌呤生物合成和苯甲酸代谢存在差异。
- 脂质组学发现二酰甘油是区分肥胖个体周围神经病变状态最显著的脂质子通路,磷脂酰胆碱、鞘磷脂、神经酰胺和二氢神经酰胺也有额外贡献。
- 按血糖状态对肥胖组进行分层不影响按周围神经病变状态的区分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Peripheral neuropathy (PN) is a frequent prediabetes and type 2 diabetes (T2D) complication. Multiple clinical studies reveal that obesity and dyslipidemia can also drive PN progression, independent of glycemia, suggesting a complex interplay of specific metabolite and/or lipid species may underlie PN. OBJECTIVE: This work aimed to identify the plasma metabolomics and lipidomics signature that underlies PN in an observational study of a sample of individuals with average class 3 obesity. METHODS: We performed plasma global metabolomics and targeted lipidomics on obese participants with (n = 44) and without PN (n = 44), matched for glycemic status, vs lean nonneuropathic controls (n = 43). We analyzed data by Wilcoxon, logistic regression, partial least squares-discriminant analysis, and group-lasso to identify differential metabolites and lipids by obesity and PN status. We also conducted subanalysis by prediabetes and T2D status. RESULTS: Lean vs obese comparisons, regardless of PN status, identified the most significant differences in gamma-glutamyl and branched-chain amino acid metabolism from metabolomics analysis and triacylglycerols from lipidomics. Stratification by PN status within obese individuals identified differences in polyamine, purine biosynthesis, and benzoate metabolism. Lipidomics found diacylglycerols as the most significant subpathway distinguishing obese individuals by PN status, with additional contributions from phosphatidylcholines, sphingomyelins, ceramides, and dihydroceramides. Stratifying the obese group by glycemic status did not affect discrimination by PN status. CONCLUSION: Obesity may be as strong a PN driver as prediabetes or T2D in a sample of individuals with average class 3 obesity, at least by plasma metabolomics and lipidomics profile. Metabolic and complex lipid pathways can differentiate obese individuals with and without PN, independent of glycemic status.
引用
- Guo K, Savelieff MG, Rumora AE, et al. Plasma Metabolomics and Lipidomics Differentiate Obese Individuals by Peripheral Neuropathy Status. J Clin Endocrinol Metab. 2022. PMID: 34878536. doi:10.1210/clinem/dgab844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。